Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 FINANCING INCLUDES LEADING U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS AND MUTUAL FUNDS  LOS ANGELES, CA, DEC. 09, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN REGISTERED OFFERING OF 19,117,646 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $5.10 PER SHARE, AND TO CERTAIN INVESTORS IN LIEU OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE 490,196 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $5.09 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE FOR THE COMMON STOCK, LESS THE $0.01 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE NET PROCEEDS TO IMMIX FROM THE OFFERING, AFTER DEDUCTING THE UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $93.7 MILLION.

IMMIX BIOPHARMA ANNOUNCES CLOSING OF UPSIZED $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

LOS ANGELES, CA, DEC. 07, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN REGISTERED OFFERING OF 19,117,646 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $5.10 PER SHARE, AND TO CERTAIN INVESTORS IN LIEU OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE 490,196 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $5.09 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE FOR THE COMMON STOCK, LESS THE $0.01 PER SHARE EXERCISE PRICE FOR EACH SUCH PRE-FUNDED WARRANT. THE GROSS PROCEEDS TO IMMIX FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS, COMMISSIONS AND OTHER OFFERING EXPENSES, ARE EXPECTED TO BE $100 MILLION. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT DECEMBER 9, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

IMMIX BIOPHARMA ANNOUNCES PRICING OF UPSIZED $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

 NXC-201 DEMONSTRATED A COMPLETE RESPONSE (CR) RATE OF 75% (15/20) (AT S/U IFE(-) LEVEL) BY INDEPENDENT REVIEW COMMITTEE 

AT ASH 2025 ORAL PRESENTATION, IMMIX BIOPHARMA REPORTS POSITIVE PHASE 2 NXC-201 RESULTS, ADVANCING TOWARD BLA SUBMISSION AS A POTENTIALLY FIRST- AND BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

- FORMER CHIMERIX (CMRX, ACQUIRED BY JAZZ FOR $935 MILLION) SENIOR COMMERCIAL LEADER MICHAEL GRABOW LED GO-TO-MARKET STRATEGY AND LAUNCH FOR RARE DISEASE THERAPEUTIC MODEYSO -

IMMIX BIOPHARMA APPOINTS CHIEF COMMERCIAL OFFICER TO DRIVE NXC-201 LAUNCH

- ORAL PRESENTATION SUNDAY, DECEMBER 7, AT ASH 2025 - LOS ANGELES, NOV. 03, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT PHASE 1/2 INTERIM RESULTS FROM ITS U.S. NXC-201 NEXICART-2 TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS HAS BEEN SELECTED FOR ORAL PRESENTATION AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY 2025 ANNUAL MEETING (ASH 2025) BEING HELD IN ORLANDO, FLORIDA, DECEMBER 69, 2025. ASH 2025 PRESENTATION DETAILS  NXC-201 TITLE FIRST 20-PATIENT SAFETY AND EFFICACY DATA FROM NEXICART-2, THE FIRST U.S. TRIAL OF CAR-T IN R/R LIGHT CHAIN (AL) AMYLOIDOSIS, NXC-201 PRESENTATION DATE/TIME (EASTERN TIME) PRESENTATION DATE: DECEMBER 7, 2025 PRESENTATION TIME: 5:45 PM - 6:00 PM ET PRESENTATION ABSTRACT NUMBER: ABS25-14730 SESSION NAME: 652.

IMMIX BIOPHARMA'S NXC-201 NEXICART-2 CLINICAL TRIAL RESULTS SELECTED FOR ORAL PRESENTATION AT ASH 2025

LOS ANGELES, CA, OCT. 14, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. ("IMMIXBIO", "COMPANY", "WE" OR "US" OR "IMMX"), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT IT WILL PRESENT AND HOST INSTITUTIONAL INVESTOR MEETINGS AT THE GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE BEING HELD NOVEMBER 10-12, 2025 IN BOSTON, MA.

IMMIX BIOPHARMA TO PRESENT AT THE GUGGENHEIM 2ND ANNUAL HEALTHCARE INNOVATION CONFERENCE

LOS ANGELES, CA, OCT. 06, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT IT WILL PRESENT A NXC-201 ABSTRACT AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY (ASH) 67TH ANNUAL MEETING AND EXPOSITION TO BE HELD DECEMBER 6-9, 2025, IN ORLANDO, FLORIDA.

IMMIX BIOPHARMA TO PRESENT ABSTRACT AT THE UPCOMING ASH 2025 ANNUAL MEETING

LOS ANGELES, CA, OCT. 01, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL PRESENT AND HOST INSTITUTIONAL INVESTOR MEETINGS AT THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE BEING HELD ON DECEMBER 2-4, 2025 AT THE LOTTE NEW YORK PALACE HOTEL IN NEW YORK, NY.

IMMIX BIOPHARMA TO PRESENT AT THE 37TH ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

 ON TRACK FOR FIRST FDA BIOLOGICS LICENSE APPLICATION (BLA) APPROVED CELL THERAPY IN ORPHAN INDICATION RELAPSED/REFRACTORY AL AMYLOIDOSIS 

IMMIX BIOPHARMA ANNOUNCES 50% ENROLLMENT MILESTONE SURPASSED IN ITS ONGOING RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL, NEXICART-2

 DR. CHANG LED XOLAIR FROM INVENTION THROUGH FDA APPROVAL AND COMMERCIALIZATION, EXCEEDING $5 BILLION IN SALES SO FAR 

Immix Biopharma, Inc.

IMMX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immix Biopharma, Inc.

IMMX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMMX